Fig. 1: Sacituzumab Govitecan (SG) inhibits tumor growth in a xenograft model of intracranial breast cancer.

Representative bioluminescent images of control and sacituzumab govitecan treated (25 mg/kg/twice weekly) mice at the start of treatment (top panels) and 2 weeks after treatment (bottom panels).